Analysis of United States Patent 12,285,430: Luminal-Active Drug Formulations
United States Patent 12,285,430, granted on April 16, 2024, to Viatris Inc., covers pharmaceutical formulations of luminal-active drugs. The patent focuses on methods for treating inflammatory bowel disease (IBD), specifically Crohn's disease and ulcerative colitis, by delivering active pharmaceutical ingredients (APIs) to the colon. The claimed technology aims to improve drug efficacy and reduce systemic side effects through targeted colonic release.
What is the core innovation described in Patent 12,285,430?
The patent protects pharmaceutical formulations designed for targeted delivery of luminal-active drugs to the colon. The innovation lies in the specific combination of components that ensure the API remains encapsulated and protected in the upper gastrointestinal tract (stomach and small intestine) and is released primarily in the colon. This targeted release mechanism is critical for drugs intended to act locally within the colonic lumen, minimizing exposure and potential adverse effects in other parts of the body.
The formulations utilize a core tablet or capsule containing the API. This core is then coated with a specific polymer system. The patent details the chemical composition and physical properties of these coating polymers, emphasizing their pH-dependent solubility. The coating is designed to remain intact at the lower pH of the stomach and the neutral to slightly alkaline pH of the small intestine. Upon reaching the higher pH environment of the colon (typically pH 6.0-7.5), the coating dissolves, releasing the API directly into the colonic lumen.
What specific drugs and indications are addressed by the patent claims?
While the patent specifies a broad category of "luminal-active drugs," it explicitly references their application in treating inflammatory bowel disease (IBD). The patent details the use of these formulations for the treatment of Crohn's disease and ulcerative colitis.
The term "luminal-active drug" refers to APIs that exert their therapeutic effect by acting within the lumen of the gastrointestinal tract. Examples of drug classes that can be formulated under this patent, particularly for IBD, include:
- Aminosalicylates: Such as mesalamine (5-ASA), balsalazide, and sulfasalazine. These are cornerstone treatments for mild to moderate IBD, acting locally to reduce inflammation in the colon.
- Corticosteroids: When formulated for targeted colonic release, certain corticosteroids can be used to manage inflammation with reduced systemic absorption.
- Other Anti-inflammatory Agents: The scope can extend to novel agents designed for localized action within the colon.
The patent does not limit itself to a single API but rather provides a formulation strategy applicable to a range of drugs that benefit from colonic targeting. This broad applicability is a key feature of the patent's protection.
What are the key features of the claimed pharmaceutical formulations?
The patent outlines several critical components and characteristics of the formulations that enable targeted colonic release:
Coating System Composition
The patent claims describe a multi-layered coating system applied to the drug core. The primary functional layer responsible for pH-dependent release is a film-forming polymer.
-
Eudragit® Polymers: Specifically, the patent frequently references methacrylic acid copolymers, commonly marketed under the Eudragit® brand by Evonik Industries. These polymers are well-established for their pH-responsive properties.
- Eudragit® L: Typically dissolves at pH > 6.0, making it suitable for release in the ileum and colon.
- Eudragit® S: Typically dissolves at pH > 7.0, targeting release more specifically in the distal colon.
The patent claims often specify combinations of these or similar polymers to achieve a precise release profile. For instance, a formulation might employ a sequential coating strategy where one polymer dissolves at a lower colonic pH, followed by another that dissolves at a higher pH, ensuring release throughout the colon.
-
Plasticizers: Compounds like triethyl citrate, acetyl tributyl citrate, or polyethylene glycol are used to improve the flexibility and film-forming properties of the polymer coating, preventing cracking.
-
Anti-adherents: Talc or magnesium stearate can be included to prevent the coated pellets or tablets from sticking together during the coating process.
-
Opacifiers/Colorants: Titanium dioxide or iron oxides may be used for aesthetic purposes or to protect the API from light.
Release Mechanism and pH Sensitivity
The core principle is the exploitation of the pH gradient along the gastrointestinal tract.
- Stomach (pH 1.5-3.5): The coating is insoluble and protects the API.
- Small Intestine (pH 5.5-7.0): The coating remains largely insoluble, or dissolves very slowly, preventing premature API release.
- Colon (pH 6.0-7.5): The coating polymers undergo a phase transition, becoming permeable or dissolving, thereby releasing the API into the colonic lumen.
The patent claims specify target dissolution profiles under various pH conditions, often using in vitro dissolution testing methodologies. For example, a claim might stipulate less than 10% release in simulated gastric fluid (pH 1.2) and less than 20% release in simulated intestinal fluid (pH 6.8) for a specific duration, followed by rapid release at pH 7.4.
Drug Content and Dosage Forms
The patent covers various dosage forms, including:
- Tablets: Solid oral dosage forms.
- Capsules: Containing the API and potentially the coating as multiparticulates.
- Pellets/Granules: Small, spherical particles containing the API, which are then typically filled into capsules or compressed into tablets. This multiparticulat
